XmAb819’s selected 400 mcg/kg IV dose produced five confirmed partial responses among 11 efficacy-evaluable patients, a 45.5% confirmed objective response rate. The Alexion settlement provides $105.0 million and ends U.S. Ultomiris royalties.
XNCR · Xencor Inc · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Xencor reported third-quarter revenue of $116.5 million and net income of $39.4 million, versus $21.0 million revenue and a $6.0 million net loss in 2025. It held $555.7 million in cash, cash equivalents and marketable debt securities.
Xencor selected 400 mcg/kg for XmAb819 as the proposed intravenous RP3D after reporting 45.5% cORR, 55% uORR and an 82% 6-month PFS Kaplan-Meier estimate. It plans to discuss a potential accelerated approval pathway with the FDA in 1H2027.